Navigation

magnesium oxide (Mag-Ox 400, Uro-Mag, Mag-Caps)

 

Classes: Antacids; Electrolytes

Dosing and uses of Mag-Ox 400, Uro-Mag (magnesium oxide)

 

Adult dosage forms and strengths

capsule

  • 140mg (equivalent to 84.5mg [6.93mEq] elemental magnesium)

tablet

  • 400mg (equivalent to 240mg [20mEq] elemental magnesium)

 

Recommended Daily Intake (Elemental Mg)

Females

  • 19-30 yr: 310 mg/day PO
  • 19-30 yr (pregnant): 350 mg/day PO
  • >31 yr: 320 mg/day PO
  • >31 yr (pregnant): 360 mg/day PO

Males

  • 19-30 yr: 400 mg/day PO
  • >31 yr: 420 mg/day PO

 

Magnesium Supplementation

Tablet (Mag-Ox): 1-2 tablets PO qDay

Capsule (Uro-Mag): 1-5 capsules PO qDay

 

Antacid

Tablet (Mag-Ox): 1 tablet PO qDay or q12hr; not to exceed 2 tablets/day

 

Renal Impairment

CrCl <30 mL/min: Caution; monitor for hypermagnesemia

 

Administration

Take with food

 

Pediatric dosage forms and strengths

capsule

  • 140mg (equivalent to 84.5mg [6.93mEq] elemental magnesium)

tablet

  • 400mg (equivalent to 240mg [20mEq] elemental magnesium)

 

Recommended Daily Intake (Elemental Mg)

1-3 years: 80 mg/day PO

4-8 years: 130 mg/day PO

9-13 years: 240 mg/day PO

14-18 years

  • Females: 360 mg/day PO
  • Pregnant females: 400 mg/day PO
  • Males: 410 mg/day PO

 

Renal Impairment

CrCl <30 mL/min: Caution; monitor for hypermagnesemia

 

Administration

Take with food

 

Mag-Ox 400, Uro-Mag (magnesium oxide) adverse (side) effects

Frequency not defined

Diarrhea with excessive dose

Gastrointestinal irritation

 

Warnings

Contraindications

Hypersensitivity

 

Cautions

Normal serum magnesium ~1.5-2.5 mg/dL

Laxative effect

Magnesium supplementation may exacerbate

Caution with renal impairment

Caution with myasthenia gravis or other neuromuscular diseases

 

Pregnancy and lactation

Pregnancy category: A; 350-400 mg/day elemental Mg recommended during pregnancy

Lactation: Distributed in breast milk; 310-360 mg/day elemental Mg recommended during lactation

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Mag-Ox 400, Uro-Mag (magnesium oxide)

Mechanism of action

Mineral; cofactor in many enzymatic reactions and essential for various metabolic functions (eg, phosphate transfer, muscle contraction, nerve conduction)

 

Pharmacokinetics

Absorption: Inversely proportional to dose; ~50% with controlled dietary intake, compared with 15-30% with high dose

Distribution sites: 50-60% (bone); 1-2% (extracellular fluid)

Protein Bound: 30% (albumin)

Excretion: Urine